AstraZeneca in the news

AstraZeneca inaugurated a new R&D center in Cambridge, Massachusetts, as part of a significant investment to boost drug discovery and US market presence.

AstraZeneca's CEO Pascal Soriot discussed the potential of Summit Therapeutics' drug ivonescimab for advanced cancer treatment combinations after AstraZeneca made a $2 billion equity investment and formed clinical collaboration agreements.

AstraZeneca's CEO stated the company has sufficient resources for continued growth past 2030, negating the need for major acquisitions.

AstraZeneca inaugurated a new $1 billion research and development center in Cambridge, Massachusetts, featuring extensive labs and aiming to significantly boost its local workforce as part of a major US investment.

AstraZeneca opened a new 570,000 square foot R&D center in Kendall Square, Cambridge, Massachusetts, to accelerate drug discovery and development in oncology, cell therapy, chronic, and rare diseases.

AstraZeneca opened a new $1 billion R&D center in Kendall Square, Cambridge, Massachusetts, planning to increase its local workforce by over 50%.

AstraZeneca will invest over $1 billion in Massachusetts, including a new R&D center, and expand its workforce by more than 50%.

AstraZeneca's CEO stated the company has adequate resources for growth past 2030, dismissing the need for a major acquisition.

AstraZeneca inaugurated a new 18-floor Kendall hub for 2,000 employees focusing on oncology and rare disease research.

AstraZeneca completed a $2 billion equity investment in Summit Therapeutics to accelerate the development of ivonescimab and entered into multiple clinical collaborations to combine its cancer medicines with ivonescimab.

AstraZeneca completed a $2 billion investment in Summit Therapeutics to advance ivonescimab and other cancer treatments, also forming collaborations for ivonescimab and Datroway.

AstraZeneca's CEO sees Summit Therapeutics' ivonescimab as a key to next-generation cancer therapies after a $2 billion investment.

AstraZeneca invested $2 billion in Summit Therapeutics, leading to a 1.7% stock drop, to test a new cancer-drug combination, with trials starting soon.

AstraZeneca and two partners are preparing to test a cancer-drug combination for breast cancer treatment.

AstraZeneca, Daiichi Sankyo, and Summit Therapeutics are collaborating on clinical trials to combine Datroway with ivonescimab for multiple cancer types, starting with a Phase III study in triple-negative breast cancer.

Summit Therapeutics, Daiichi Sankyo, and AstraZeneca are collaborating on clinical trials to combine ivonescimab with Datroway for various solid tumors, starting with a Phase III study in triple-negative breast cancer.